in this issue
EnviroTech :: R&D
Nicholas Piramal to Spin Off R&D Unit
11:42 AM MDT | September 14, 2007 | Deepti Ramesh
Pharmaceutical company Nicholas Piramal India Ltd. (NPIL; Mumbai) says it plans to demerge its R&D unit, creating a separate, independent company focused on developing novel drugs, otherwise known as new chemical entities (NCE). The demerger will be in the form of a spin-off to shareholders. NPIL will have an 18% stake in the new company, and NPIL’s shareholders will hold the rest. A proposal for the demerger has been approved by the NPIL board, and awaits regulatory and other approvals. NPIL will transfer net assets worth about $24 million to the new...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee